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640Introduction: The Female Sexual Function Index (FSFI) is a patient-reported outcome measure measuring
female sexual dysfunction. The FSFI-19 was developed with 6 theoretical subscales in 2000. In 2010, a shortened
version became available (FSFI-6).
Aim: To investigate the measurement properties of the FSFI-19 and FSFI-6.
Methods: A systematic search was performed of Embase, Medline, and Web of Science for studies that
investigated measurement properties of the FSFI-19 or FSFI-6 up to April 2018. Data were extracted and
analyzed according to COnsensus-based Standards for the selection of health Measurement INstruments
(COSMIN) guidelines. Evidence was categorized into sufficient, insufficient, inconsistent, or indeterminate, and
quality of evidence as very high, high, moderate, or low.
Main Outcome Measures: The Main Outcome Measure is the evidence of a measurement property, and the
quality of evidence based on the COSMIN guidelines.
Results: 83 studies were included. Concerning the FSFI-19, the evidence for internal consistency was sufficient
and of moderate quality. The evidence for reliability was sufficient but of low quality. The evidence for criterion
validity was sufficient and of high quality. The evidence for structural validity was inconsistent of low quality.
The evidence for construct validity was inconsistent of moderate quality. Concerning the FSFI-6, the evidence
for criterion validity was sufficient of moderate quality. The evidence for internal consistency was rated as
indeterminate. The evidence for reliability was inconsistent of low quality. The evidence for construct validity
was inconsistent of very low quality. No information was available on structural validity of the FSFI-6, and
measurement error, responsiveness, and cross-cultural validity of both FSFI-6 and FSFI-19.
Clinical Implications: Conflicting and lack of evidence for some of the measurement properties of the FSFI-19
and FSFI-6 indicates the importance of further research on the validity of these patient-reported outcome
measures. We advise researchers who use the FSFI-19 to perform confirmatory factor analyses and report the
factor structure found in their sample. Regardless of these concerns, the FSFI-19 and FSFI-6 have strong criterion
validity. Pragmatically, they are good screening tools for the current definition of female sexual dysfunction.
Strength & Limitation: A strong point of the review is the use of predefined guidelines. A limitation is the use
of a precise rather than a sensitive search filter.
Conclusions: The FSFI requires more research on structural validity (FSFI-19 and FSFI-6), reliability
(FSFI-6), construct validity (FSFI-19), measurement error (FSFI-19 and FSFI-6), and responsivenessvember 29, 2018. Accepted March 2, 2019.
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Outcome MeasureINTRODUCTION
Sexual dysfunction refers to a problem that prevents people
experiencing satisfaction from sexual activity. A first model of
female sexual dysfunction (FSD) was composed in 1998 with 4
categories of disorders (desire, arousal, orgasm, and pain) as
described in the Diagnostic and Statistical Manual of Mental
Disorders-IV (DSM-IV) and the International Statistical Classi-
fication of Diseases and Related Health Problems-10 (ICD-10)
at that time.1
In 2000, the Female Sexual Function Index (FSFI) was
developed to measure female sexual (dys)function,2 based on the
models described in the DSM-IV and ICD-10. The FSFI is a
19-item patient-reported outcome measure (PROM), consisting
of 6 separate domains of female sexual function, namely desire
(items 1e2), arousal (3e6), lubrication (7e10), orgasm
(11e13), satisfaction (14e16), and pain (17e19). Initial vali-
dation showed good internal consistency for all scales in a study
sample drawn from the general population, as well as in sub-
groups of FSD patients and control subjects (Cronbach’s a ¼
0.82e0.97). Test-retest reliability was acceptable (r ¼
0.79e0.86). Known-groups comparison was tested between
FSD patients and control subjects, with significant differences
on all domains of the FSFI-19. Divergent validity (as measured
with the Locke-Wallace Marital Adjustment Test3) was good
(r ¼ 0.04e0.43), except for the FSFI satisfaction scale (r ¼
0.40e0.72).2 In 2010, a 6-item version (FSFI-6) to measure
FSD was developed. The 6 items were selected by inspecting the
receiver operating characteristic curves of each item of the FSFI-
19 for distinguishing between women with and without FSD.
The best-performing item for each of the 6 domains of the FSFI-
19 was selected for use in the FSFI-6.4 The FSFI-6 showed
acceptable internal consistency (Cronbach’s a ¼ 0.789),
acceptable test-retest reliability (Pearson correlation ¼ 0.95), and
good criterion validity with a cutoff of  19 (sensitivity ¼ 0.96;
specificity ¼ 0.91).
With the release of the DSM-5 in 2013, the model for FSD
has seen some changes. Of particular interest, 1 desire disorder
(sexual aversion disorder) was removed, whereas the remaining
desire disorder (hypoactive desire disorder) was merged with the
arousal dysfunction disorder.5 This new model suggests that
desire and arousal may not be separate constructs in the context
of FSD. Interestingly, the original validation study found a
5-factor structure where desire and arousal were part of the same2019;16:640e660construct. This factor was split into 2 subscales due to clinical
considerations.2
The FSFI-19 and FSFI-6 are widely used in clinical practice as
a screening tool for FSD, as well as in clinical trials as an outcome
measure. As such, it is of importance to assess the measurement
properties of the FSFI-19 and FSFI-6, to determine whether they
are fit to use in clinical and scientific contexts. To our knowl-
edge, the measurement properties of the FSFI-19 and FSFI-6
have not yet been systematically reviewed. As such, the aim of
this study was to investigate whether the initial good results
regarding the measurement properties of the FSFI-19 and FSFI-6
were confirmed in later studies. Of particular interest is structural
validity, and the question is whether the original 6-factor struc-
ture is challenged in favor of a 5-factor structure where desire and
arousal are part of the same construct. The results of this sys-
tematic review are relevant for the use of the FSFI to monitor
sexual dysfunction in women in clinical trials and practice.
In this review, we followed the COnsensus-based Standards
for the selection of health Measurement INstruments (COS-
MIN) methodology.6 This methodology is based on a taxonomy
and definitions of measurement properties for PROMs7
including content validity (assessment of whether the FSFI rep-
resents all facets of FSD), structural validity (assessment of
whether the FSFI subscales are singular constructs), internal
consistency (assessment of whether FSFI items measuring the
same construct are consistent in their results), cross-cultural
validity (assessment of whether there are structural differences
in validity of the FSFI between populations), reliability (assess-
ment of whether the FSFI reproduces similar scores when FSD
has been stable), measurement error (assessment of systematic
and random error between the FSFI score and the true score of a
patient), criterion validity (assessment of how well the FSFI score
is an adequate reflection of FSD diagnosis), hypotheses testing
for construct validity (assessment of whether the FSFI measures
the construct of FSD), and responsiveness (assessment of how
well the FSFI measures FSD change over time).METHODS
Literature Search
The literature search was part of a larger systematic review
(Prospero ID 42017057237), which investigated the measure-
ment properties of 39 different PROMs (including the FSFI)
642 Neijenhuijs et almeasuring quality of life of cancer survivors included in an eHealth
application called “Oncokompas”.8e11 The databases Embase,
Medline, andWeb of Science were searched using the search terms
of the PROM’s name and acronyms, combined with a precise
search filter for measurement properties.12 The search was per-
formed in January 2017. A search update was performed on April
13, 2018, to search for recent studies. This search update also used
broader search terms across all years (not only 2017e2018),
because not all acronyms of the FSFI were correctly specified in the
original search. Appendix A contains the full search terms. Due to
the limitation of the sensitivity of the precise filter (93% sensi-
tive),12 a manual search using rudimentary search filters was per-
formed in Google Scholar and PubMed to check for any
prominent records missed in the search update.Inclusion and Exclusion Criteria
Studies were included when they reported original data on 1
of the following measurement properties of the FSFI: structural
validity (whether the hypothesized measurement model is
confirmed), internal consistency (the degree of interrelatedness
among the items of the measure), reliability (the proportion of
total variance between multiple measurements, which is due to
“true” differences between measurements), measurement error (a
measure of systematic and random error in change scores), cri-
terion validity (whether the measure is an adequate reflection of a
gold standard; in the case of the FSFI, this is most often a
diagnosis of FSD), cross-cultural validity (whether the test can be
interpreted similarly in different cultures), responsiveness
(whether the measure is capable of measuring change over time
in the construct to be measured), and hypothesis testing for
construct validity (whether the test measures the construct it
proposes to measure), which consists of known-groups compar-
ison (a comparison between groups known to have differences on
the construct), convergent validity (correlations with other
measures that should be related), and divergent validity (corre-
lations with other measures that should be unrelated). While of
importance for establishing validity, content validity was not
investigated because it was beyond the scope of the current re-
view. Validation studies on other PROMs that also reported
original data on the FSFI were included as well.
Studies that were only available as abstracts or conference
proceedings were excluded, as well as non-English publications.
Titles and abstracts, and the selected full-texts were screened by 2
independent reviewers (K.N./M.V./K.H./N.H.). Disagreements
were discussed until consensus was reached.Data Extraction
Data on each of the measurement properties defined by the
COSMIN taxonomy7 was extracted by 2 independent researchers
(K.N./A.vdH./H.M./E.V./N.H.). Relevant data included the type
of measurement property, its results, and information on missing
values. Information on the type of research (psychometric or not),
specified research aim, sample size, population information, andwhich version of the FSFI was used, was also extracted. Disagree-
ments were discussed until consensus was reached.Data Analysis
Data analysis consisted of 3 consecutive steps. First, the quality
of the included studies was rated using the 4-point scoring system
of the COSMIN checklist.13 Methodologic aspects regarding
design requirements and preferred statistical methods, specific to
each measurement property under consideration, were rated as
either “inadequate,” “doubtful,” “adequate,” or “very good.” The
methodologic quality was summarized per measurement property
per study, as the lowest score received on any of the methodologic
aspects. The complete criteria for study quality per measurement
property are documented elsewhere.13 Appendix B contains the
final study quality ratings.
Second, each measurement property in each individual study
was rated as sufficient, insufficient, or indeterminate, according to
criteria for good measurement properties included in the COS-
MIN guidelines for systematic reviews of PROMs. The complete
criteria for rating these measurement properties are documented
elsewhere.6 These ratings were qualitatively summarized to
determine the overall rating of the measurement property for the
FSFI. If all studies indicated a “sufficient,” “insufficient,” or
“indeterminate” rating for a specific measurement property, the
overall rating of this measurement property was rated accordingly.
If there were inconsistencies between studies, explanations were
explored (eg, differences in methodologic quality, differences in
population, etc). If explanations were found, they were discussed
until consensus was reached regarding the overall rating of the
measurement property. If no explanations were found, the overall
rating would be inconsistent.
Third, the overall rating of evidence per measurement prop-
erty was supplemented by a level of quality of evidence, using a
modified Grading of Recommendations Assessment, Develop-
ment and Evaluation approach from the COSMIN methodol-
ogy.6 This approach takes into account (i) study quality, (ii)
directness of evidence, (iii) inconsistency of results, and (iv)
precision of evidence (number of studies and sample size). The
overall quality of evidence was rated as high, moderate, low, or
very low. Measurement properties that were rated as indetermi-
nate in the previous step, did not receive a rating in this third
step as there was no evidence to rate.
All ratings (methodologic quality, measurement property rat-
ing, and Grading of Recommendations Assessment, Develop-
ment, and Evaluation rating) were made by 2 independent
researchers (K.N./K.H./N.H.). Discrepancies in ratings were
discussed until consensus was reached.RESULTS
Search Results
The initial search identified 1,401 non-duplicate abstracts, of
which 174 were relevant to the FSFI (Figure 1). A total of 155J Sex Med 2019;16:640e660
Figure 1. PRISMA diagram.
Measurement Properties of the FSFI 643abstracts and 11 full texts were excluded from the initial search,
because they did not provide unique information on a mea-
surement property. The search update up to April 2018 identi-
fied 1,415 more non-duplicate abstracts. A total of 1,229
abstracts and 110 full-texts were excluded from the search up-
date, because they did not provide unique information on a
measurement property of the FSFI. 2 full texts were excluded
during data extraction.
In total we included 83 studies: 75 on the FSFI-19,2,14e87 5 on
the FSFI-6,4,88e91 and 3 on adaptations of the FSFI-19: a version
specific for breast cancer survivors,92 a version for life-long sexual
dysfunction,93 and a version with an added item concerning vagi-
nismus.94 An overview of study characteristics is provided inTable 1.
The combined body of the 75 studies on the FSFI-19, and the
5 studies on the FSFI-6 reported on all measurement properties,
except measurement error, responsiveness, and cross-cultural
validity. The 3 studies on adaptations of the FSFI-19 reported
on structural validity, internal consistency, test-retest reliability,
and construct validity of original subscales of the FSFI-19.
Structural Validity
29 studies2,16,19,20,24e27,33,38,39,41,44,45,47,50,58,59,63,65,73e75,
78,82e85,92,93 reported on structural validity of the FSFI-19, of
which 8 reported multiple analyses2,33,50,75,78,83,85,93 (Table 2).
Methodologic quality of these studies was rated as “very
good”2,19,44,47, “adequate,”16,20,24,25,27,33,38,39,41,45,50,58,73e75,78,
82e85,92,93 or “inadequate”.2,59,65 The “inadequate” ratings wereJ Sex Med 2019;16:640e660due to sample sizes that were too small (“other flaws” in COS-
MIN methodologic quality).
3 studies of “very good” quality,19,44,93 1 study of “adequate”
quality,78 and 1 study of “inadequate” quality59 confirmed the
hypothesized 6-factor structure and were thus rated as sufficient.
8 studies of “adequate” quality25,33,47,50,74,78,83,85 showed a poor
fit for the 6-factor structure. 2 of these studies tested and showed
support for a 5-factor structure.33,50
19 studies of “adequate” quality,16,20,24,27,33,38,39,41,45,50,
58,63,73,75,83e85,92,93 and 2 studies of “inadequate” quality2,65
performed analyses (mostly Principal Component Analysis)
without reporting fit statistics; therefore, results were rated as
indeterminate. Noteworthy is that 5 studies showed support for a
6-factor structure,16,65,75,82,85 whereas 11 studies showed sup-
port for a 5-factor structure with a merging of the desire and
arousal subscales.2,20,24,33,38,50,58,63,82,92,93 1 study showed sup-
port for a 5-factor structure with a different merging of sub-
scales,39 and 7 studies showed support for <5
factors.27,41,45,73,82e84 1 study used item response theory analysis
and was rated indeterminate because no fit measures were re-
ported.26 None of the studies that investigated the FSFI-6 4,88e91
reported on structural validity.
Internal Consistency
36 studies reported on internal consistency of the FSFI-
192,14,16,19,20,27,29,33,36,38e40,44,47,48,50,52,58,59,63,65,68,70,72e76,78,
80,82,83,85,86,93,94 (Supplementary Table 1). Methodologic
644 Neijenhuijs et alquality was rated as “very good,”2,14,16,19,20,33,36,38,40,44,47,52,58,
63,68,70,73e76,78,80,82,83,85,93,94
“adequate”,48,59,72 “doubt-
ful”,29,39 or “inadequate”.27,86 The “inadequate” ratings were
due to reporting of Cronbach’s a values for only the total score of
the FSFI-19. The “doubtful” ratings were due to the reporting of
Cronbach’s a for an adapted version of a subscale.
23 studies2,14,16,19,20,33,38,40,44,47,52,58,68,70,73,75,76,78,80,82,83,
93,94 of “very good” quality, 2 studies of “adequate” qual-
ity,59,72 1 study of “doubtful” quality,39 and 1 study of “inade-
quate” quality86 reported Cronbach’s a values that were rated as
sufficient (a  0.70 and  0.95) for all subscales. 4 studies of
“very good” quality,36,63,74,85 1 study of “adequate” quality,48 1
study of “doubtful” quality,29 and 1 study of “inadequate”
quality27 reported multiple Cronbach’s a values that were rated
as insufficient (a < 0.70 or > 0.95).
4 studies reported on internal consistency of the
FSFI-64,88,89,91 (Supplementary Table 1). Methodologic quality
was rated as “very good”4,88,91 or “inadequate”.89 The inadequate
rating was due to unclear reporting on which items the Cron-
bach’s a was calculated. The evidence of internal consistency was
rated as indeterminate for all 4 studies, because unidimension-
ality of the FSFI-6 was not investigated (see Structural Validity),
which is a prerequisite for interpreting internal consistency.
Test-Retest Reliability
21 studies2,16,19,22,27,33,36,39,50,58,63,65,68,70,73e75,80,84e86 re-
ported on test-retest reliability of the FSFI-19 (Table 3). Meth-
odologic quality was rated as “ade-
quate”,22,33,58,84,85 “doubtful”,2,16,19,27,36,39,50,63,65,68,70,73,80,86
or “inadequate”.74,75 The “doubtful” ratings were due to the use
of Pearson correlation instead of the intraclass correlation co-
efficients. The “inadequate” ratings were due to a very small sample
size (“other flaws” in COSMINmethodologic quality),74 or due to
dissimilar test conditions.75
5 studies of “adequate” quality,22,33,58,84,85 12 studies of
“doubtful” quality,2,16,19,36,39,50,63,65,70,73,80,86 and 2 studies of
“inadequate” quality74,75 reported test-retest values that were
rated as sufficient. 2 studies of “doubtful” quality27,68 reported
test-retest values that were rated as insufficient.
2 studies reported on test-retest reliability of the FSFI-64,89
(Table 3). Methodologic quality was rated as “adequate”,89 or
“doubtful”.4 The “doubtful” rating was due to use of Pearson
correlation instead of the intraclass correlation coefficient.
1 study of “doubtful” quality4 reported test-retest values that
were rated as sufficient. 1 study of “adequate” quality reported
test-retest values that were rated as insufficient.
Construct Validity (Hypothesis Testing)
Known-group comparison
23 studies2,14,16,20,29,33,39,48,52,53,58,64,65,68,70,73e76,80,82,85,86
reported on known-group comparison of the FSFI-19
(Supplementary Table 2). Known-group differences wereinvestigated in relation to urologic/gynecologic patients vs con-
trols,14,39,48,80 FSD patients vs controls,2,16,33,53,58,70,73,75,82
cancer treatment modality,20 patients with hypoactive sexual
desire disorder (HSDD) vs controls,29,52,64,68 diabetic patients vs
controls,65 premenopausal women vs postmenopausal
women,74,85 age,76 marriage status,85 and women experiencing
subjective sexual distress vs controls.86 Methodologic quality was
rated as “adequate” for all 23 studies. In all 23 studies the
known-group comparisons provided evidence of sufficient
construct validity, as the hypothesized differences between
groups were confirmed. None of the studies that investigated the
FSFI-64,88e91 reported on known-group comparisons.
Convergent Validity
49 studies reported on convergent validity of the FSFI-19
(Supplementary Table 3). The FSFI-19 was compared to mea-
sures measuring sexual function and sat-
isfaction,15,17,18,21,23e25,28,29,31,33,37,46,53,55,57,58,60,62,64,67e69,71,
72,74,78,79,92,93 quality of life,19,92 mental health measures,20,39
physical functional problems,20,30,32,34,49,54,66,74,77,81,83,87 rela-
tionship quality,20,39,52 and body image.35,42,43,56,60 A full list of
comparison measures can be found in Supplementary Table 3.




quate”.53 The “inadequate” rating was due to serious concerns
regarding the measurement properties of the comparator in-
strument. The “doubtful” ratings were due to concerns regarding
the measurement properties of the comparator instrument. 28
studies of “adequate” rating,15,19,23,24,28e31,35,37,46,49,54e57,60,
66e69,71,72,74,77,78,81,87,93 2 studies of “doubtful” rating,33,64
and 1 study of “inadequate” quality,53 provided correlations
rated as sufficient. 14 studies of “adequate” rat-
ing,17,20,21,25,32,34,39,42,43,52,60,62,79,83 and 2 studies of “doubt-
ful” rating,58,92 provided correlations rated as insufficient. 1
study was rated as indeterminate, because not enough informa-
tion was given for a reliable interpretation.18
4 studies reported on convergent validity of the FSFI-6
(Supplementary Table 3). The FSFI-6 was compared to coital
frequency,88 educational level,88 partner educational level,88
age,88 partner age,88 waist circumference,88 hot flush in-
tensity,88 FSFI-19,89 British National Survey of Sexual Attitudes
and LifestyleseSexual Function,90 Menopause Rating Scale,91
and Hospital Anxiety and Depression Scale.91 Methodologic
quality was rated as “adequate”,89e91 or “doubtful”.88 The
“doubtful” rating was due to concerns regarding the measure-
ment properties of the comparator instrument. 2 studies of
“adequate” quality89,90 reported correlations rated as sufficient. 1
study of “adequate” quality,91 and 1 study of “doubtful” qual-
ity88 reported correlations rated as insufficient.
Divergent Validity
8 studies reported on divergent validity of the
FSFI-192,14,19,48,58,68,76,92 (Supplementary Table 4).J Sex Med 2019;16:640e660
Table 1. Characteristics of included studies
Reference Population Sample size Main aim of study
FSFI-19
Achimas-Cadariu et al14 Female patients of reproductive age treated
for premalignant and malignant pathology
of the uterine cervix
102/204 To investigate the associations among quality of life determinants on a sample
of female patients of reproductive age (102 patients and 102 healthy control
subjects), surgically treated (conization) for preinvasive and invasive
pathology (cervix dysplasia and microinvasive carcinoma)
Ahmed et al15 Premenopausal women 241 To assess sexually related personal distress among premenopausal women with
sexual dysfunction via a validated Arabic version of the original FSDS
Anis et al16 Egyptian women 855 To validate the ArFSFI
Aydin et al17 Turkish women visiting the urogynecology
clinic
248 To develop a Turkish version of the FSDS-R, to evaluate its psychometric
reliability and validity, and to estimate the optimal cutoff score that
corresponds best to the clinical diagnosis of sexual dysfunction
Azimi Nekoo et al18 Married and potentially sexually active Iranian
women
1,966 To determine the psychometric properties of the Iranian version of the FSDS-R
in a population sample of Iranian women
Bartula et al19 Breast cancer patients 399 Assess extent to which FSFI is applicable for breast cancer patients
Baser et al20 Female cancer survivors 181 Systematic evaluation of the factor structure, reliability, and construct validity of
the FSFI for measuring the sexual functioning of female cancer survivors
Bloemendaal et al21 Dutch women 323 Validate the Dutch version of the SESII-W
Borello-France et al22 Female patients with a relapsing form of MS 48 To assess the test-retest reliability of the U-UDI and the FSFI in women with MS
Bornefeld-Ettmann
et al23
German-speaking women 465 The German translation of the SSEI-SF by Zeanah and Schwarz (1996) was
validated via an online survey with 557 women and then investigated in a
clinical sample of women suffering from PTSD after sexual and physical
abuse compared with healthy controls
Burri et al24 Sexually active Swiss women 309 To evaluate the validity and utility of the German version of the SCS-W by
assessing content, convergent, and discriminant validity
Carpenter et al25 Midlife postmenopausal women 93 To evaluate whether a single item from the FSDS-R could be identified to use to
screen midlife women for bothersome diminution in sexual function
Carpenter et al26 Peri- and postmenopausal women reporting
hot flashes
898 To evaluate whether a subset of items on the 19-item English-language FSFI
would perform as well as the full length FSFI in peri- and postmenopausal
women
Chang et al27 Pregnant women receiving prenatal
examinations
108 To translate the FSFI from English to traditional Chinese, and to evaluate the
reliability and validity of this new version for pregnant women
Clayton et al28 Female patients with diagnosis of HSDD 90 To assess the reliability and validity of the SIDI-F as a measure of HSDD severity
Clayton et al29 American (N ¼ 220) and European
(N ¼ 253) women going through FSD
diagnosis
473 To estimate the reliability and validity of the SIDI-F as a measure of HSDD
severity
Constantine et al30 American and British women 589 To create a valid and responsive summary score for the PISQ-IR
DeRogatis et al31 Postmenopausal female patients aged
40e65 with spontaneous amenorrhea or
bilateral oophorectomy with or without
hysterectomy at least 6 months before
study






























Reference Population Sample size Main aim of study
Eaton et al32 Female cancer survivors 175 To develop and validate brief clinical measurements to facilitate the identification
of vulvovaginal symptoms in patients with and survivors of cancer
Fakhri et al33 Iranian gynecological outpatients 448 To translate, validate, and enhance cross-cultural comparability of the FSFI-IV
Farkas et al34 Female patients diagnosed with Pelvic Organ
Prolapse, Urinary Incontinence, or Fecal
Incontinence
178 To translate the PISQ-IR into Hungarian and to validate the translated PISQ-IR
Ferguson et al35 Women visiting gynecologic oncology
outpatient clinic
268 To confirm the factor structure of the Sexual Adjustment and Body Image Scale
using a confirmatory factor analysis
Filocamo et al36 Italian women visiting urological and
gynecological clinics
409 To perform a linguistic validation of the Italian version of the FSFI
Flynn et al37 American female cancer patients 430 Validation of PROMIS sexual function and satisfaction scales
Forbes et al38 Sexually active Australian women 336 To examine the measurement capabilities of the IIEF and FSFI based on data
collected from an online study in 2010
Ghassamia et al39 Iranian women 562 To examine the psychometric properties of a P-FSFI among a sample of healthy
Iranian women
Heng et al41 Malaysian women visiting infertility clinic 150 To determine the construct of the phases of the female SRC among women
attending an infertility clinic in a Malaysian tertiary center
Herbenick et al42 American women attending sex toy parties 1,937 To establish a reliable and valid measure of female genital self-image, the FGSIS,
and to assess the relationship between scores on the FGSIS and women’s
sexual function
Herbenick et al43 American women 2,056 To assess the reliability and validity of the FGSIS, its model of fit, and its
association with women’s scores on the FSFI in a nationally representative
probability sample of women in the United States ages 18e60
Hevesi et al44 202 university students, 177 patients with
endometriosis, and 129 patients with
polycystic ovary syndrome; from Hungary
508 To investigate whether female sexual function is best understood as a
multidimensional construct or, alternatively, whether a common underlying
factor explains most of the variance in FSFI scores
Ismail et al45 178 female patients with diabetes, and 175
women without diabetes from Malaysia
353 To compare the components of sexual responses between Malaysian women
with type 2 diabetes mellitus and those without the disease
Jing et al46 Breast cancer survivors 246 To develop a Quality of Sexual Life Questionnaire in Breast Cancer Survivors and
determine its validity and reliability
Kalmbach et al47 Female undergraduate students 409 To assess factor structures of the FSFI, MSFI (adapted for this investigation),
and PFSF in young, healthy men and women
Likes et al48 43 female patients with vulvar excisions for
vulvar intraepithelial neoplasia; 43
age-matched controls
86 To extend the validation of the FSFI to include women with vulvar excisions for
vulvar intraepithelial neoplasia
Liu et al49 Chinese female patients with interstitial
cystitis and bladder pain syndrome
90 To examine whether adding a sexual dysfunction domain to the UPOINTsystem
improves the association with IC-BPS symptom severity due to a high
prevalence of sexual dysfunction in women
Liu et al50 Female inpatients with cervical cancer 215 To examine the psychometric properties and performance of the CVFSFI among

























Reference Population Sample size Main aim of study
Ma et al51 Chinese women 500 To establish clinical cutoff scores for the CVFSFI and to evaluate the prevalence
of FSD in urban Chinese women
Meston et al52 71 female patients with female orgasmic
disorder, 44 female patients with
hypoactive sexual desire disorder, and 71
healthy women
186 To extend the validation of the FSFI to include women with a primary clinical
diagnosis of female orgasmic disorder or hypoactive sexual desire
Meston et al53 American women 172 To develop a comprehensive, multifaceted, valid, and reliable self-report measure
of women’s sexual satisfaction and distress
Mestre et al54 118 not sexually active women, and 150
sexually active women
268 To transculturally adapt the PISQ-IR into Spanish
Mohammadi et al55 Iranian married women with MS 226 To translate and validate the MSISQ-19 in women with MS in Iran
Mohammed et al56 Egyptian married women 244 To translate the original English version of the FGSIS into Arabic and validate the
Arabic version
Nimbi et al57 Italian women 626 To test the psychometric characteristics of the Italian version of the SMQ
focusing on the Automatic Thoughts subscale
Nowosielski et al58 85 Polish female patients with FSD, 104
Polish women without FSD
189 To develop a Polish version of the FSFI
Opperman et al59 Canadian women 85 To evaluate and compare 4 models of the FSFI: (i) single-factor model, (ii)
6-factor model, (iii) second-order factor model, and (iv) 5-factor model
combining the desire and arousal subscales
Pakpour et al60 Iranian female population sample
(n ¼ 2,675), Iranian female patients with
FSD (n ¼ 295), Iranian female patients
with type 2 diabetes (n ¼ 449)
3,419 The purpose of this study was the translation and validation of the SQOL-F in
Iranian women
Pakpour et al61 Iranian female students 1,877 To investigate the psychometric properties of a translated and culturally adapted
FGSIS-I in a sample of college women
Pascoal et al62 Heterosexual sexually active women involved
in a dyadic relationship
278 To describe the development and validation of the Beliefs About Sexual
Functioning Scale
Rehman et al63 Bilingually educated women in a stable sexual
relationship
116 To translate, cross-culturally adapt, and perform a psychometric validation of an
Urdu translation of the FSFI
Rellini et al64 Female patients with female sexual arousal
disorder
24 To provide empiric evidence on the sensitivity of different types of measures for
detecting treatment-induced changes in FSD diagnosis
Rillon-Tabil et al65 Ambulatory women 85 To translate and validate the FSFIeFilipino version
Rogers et al66 American and British female patients with
pelvic floor disorders
589 To create a valid, reliable, and responsive sexual function measure in women
with PFDs for both SA and NSA women
Rosen et al2 Healthy women 259
Rosen et al67 American women reporting normal sexual
function
329 To develop and psychometrically validate a self-administered Female Sexual





























Reference Population Sample size Main aim of study
Ryding et al68 50 Swedish female patients with hypoactive
sexual desire disorder, and 58 age-
matched healthy Swedish women
108 To investigate the psychometric properties of the Swedish version of the FSFI
Selcuk et al69 71 Turkish female patients with pelvic
problems, and 38 Turkish healthy women
109 To validate the Turkish versions of the SHOW-Q for Turkish-speaking women
Sidi et al70 Married Malaysian women 230 To validate the Malay version of the FSFI
Sills et al71 Premenopausal female patients diagnosed
with HSDD
448 To use the outcome of item response analyses of blinded data from 2
randomized, placebo-controlled trials, to assist in the revision of the scale
Stephenson et al72 Adult American women in a monogamous
heterosexual relationship reporting sexual
difficulties
97 To assess the correlations between FSFI scores and information regarding
specific rates of functional impairment gained via clinical interview; and to
assess the specificity of FSFI subscale scores in reflecting corresponding
aspects of sexual function
Sun et al73 85 Chinese women seeking regular health
check-up, 145 Chinese women who
accompanied patients, and 98 Chinese
female patients with medical illness not
affecting sexual function
328 To develop and validate the CVFSFI to assess FSD in China
Takahashi et al74 Healthy Japanese women in partnered
relationships
126 To develop the FSFI-J 3-month version, and to measure its psychometric
reliability and validity
Ter Kuile et al75 234 Dutch female patients with FSD, and 108
Dutch women without FSD
342 To investigate the psychometric properties of the FSFI and the Female Sexual
Distress Scale within a Dutch population
Trudel et al76 Canadian women >65 years old in a
relationship
143 To validate the FSFI in an older (65 years), non-clinical population of
francophone women living with their spouses in Quebec
Trutnovsky et al77 German female patients visiting
urogynecologic clinics for pelvic floor
dysfunction
197 To translate the PISQ-IR into German and to clinically validate it in a
German-speaking population
Vallejo-Medina et al78 Colombian adult women 925 To adapt and validate the FSFI to Spanish language in a Colombian sample
Velten et al79 German adult women 2,206 To assess the psychometric properties of a German version of the SESII-W
Verit et al80 100 female patients with CPP and 100
age-matched women without CPP
200 To investigate the validity and reliability of FSFI in women with chronic pelvic
pain
Wang et al81 Chinese women visiting a urogynecologic
clinic
106 To translate and validate the Mandarin Chinese version of PISQ-IR for global use
Wiegel et al82 307 female patients with FSD diagnoses, and
261 healthy women
568 To cross-validate the FSFI in several samples of women with mixed sexual
dysfunctions (n ¼ 568) and to develop diagnostic cutoff scores for potential
classification of women’s sexual dysfunction
Witting et al83 Finnish female adult twins 2,081 To validate the FSFI in Finnish
Wolpe et al84 Brazilian female physical therapy students 246 To assess the psychometric properties of the FSFI applied to the VAS
Wylomanski et al85 French women attending gynecology
consultation

























Reference Population Sample size Main aim of study
Zachariou et al86 18 Greek female patients with FSD, and 99
Greek women without FSD
117 To linguistically validate the Greek version of the FSFI
Zohre et al87 100 Iranian healthy women, 200 Iranian
female patients suffering from urinary
incontinence with or without pelvic organ
prolapse
200 To translate the PISQ-12 and provide evidence for psychometric properties
FSFI-19 Sexual Desire
subscale only
Gerstenberger et al40 American and Canadian women 618 & 892 To define and validate a specific cut point on the SD domain for differentiating
women with and without hypoactive sexual desire disorder
FSFI-19; FSFI-LL
Burri et al93 British female twins FSFI-19: 1,056;
FSFI-LL: 744
To develop a modified version of the widely used FSFI-LL, and to evaluate the
psychometric properties and aptness of this new version
FSFI-20 (added item for
vaginismus)
Carvalho et al94 Portuguese women 1,425 To test, using structural equation modeling, 5 conceptual, alternative models of
female sexual function, using a sample of women with sexual difficulties and
a sample of women without sexual problems
FSFI-BC (34 items)
Bartula et al92 Australian breast cancer survivors 596 To determine the reliability, validity, and acceptability of the FSFI-BC
FSFI-6
Chedraui et al88 Ecuadorian women 904 To assess sexual function and related factors in mid-aged Ecuadorian women
Isidori et al4 Women attending a screening visit for sexual
and reproductive dysfunction
160 Development of short-form version of FSFI
Lee et al89 Korean female patients who visited
outpatient center for uterine cancer
220 To evaluate the validity and reliability of the FSFI-6K
Mitchell et al90 1,262 population sample, and 100 patients
with sexual problems. Count of women
unspecified.
1362 Development of a new measure of sexual function for the third British National
Survey of Sexual Attitudes and Lifestyles
Pérez-López et al91 Female patients attending gynecologic and
obstetric healthcare facilities
179 To assess sexual function and related factors in middle-aged Spanish women
ArFSFI ¼ Arabic version of the Female Sexual Function Index; CPP ¼ chronic pelvic pain; CVFSFI ¼ Chinese version of the Female Sexual Function Index; FGSIS ¼ Female Genital Self-Image Scale; FGSIS-I ¼
Female Genital Self-Image ScaleeIranian version; FSD ¼ female sexual disorder; FSDS ¼ Female Sexual Distress Scale; FSDS-R ¼ Female Sexual Distress ScaleeRevised; FSFI ¼ Female Sexual Function
Index; FSFI-6K ¼ Female Sexual Function Index-6eKorean version; FSFI-BC ¼ breast cancerespecific adaptation of the Female Sexual Function Index; FSFI-IV ¼ Female Sexual Function Indexe Iranian
version; FSFI-J ¼ Female Sexual Function IndexeJapanese translation; FSFI-LL ¼ Female Sexual Function Index that allows assessment of women’s lifelong sexual function; HSDD ¼ hypoactive sexual
desire disorder; IC-BPS ¼ interstitial cystitis and bladder pain syndrome; MS ¼multiple sclerosis; MSFI ¼Male Sexual Function Index; NSA ¼ not sexually active; PFD ¼ pelvic floor disorder; PFSF ¼ Profile
of Female Sexual Function; P-FSFI ¼ Persian language version of the Female Sexual Function Index; PISQ-IR ¼ Pelvic Organ Prolapse/Incontinence Sexual QuestionnaireeInternational Urogynecology
Association Revised; PISQ-12 ¼ Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire; PISQ-IR ¼ Pelvic Organ Prolapse/Incontinence Sexual Questionnaire IUGA-Revised; PTSD ¼ post-
traumatic stress disorder; SA ¼ sexually active; SCS-W ¼ Sexual Complaints Screener for Women; SESII-W ¼ Sexual Excitation/Sexual Inhibition Inventory for Women; SHOW-Q ¼ Sexual Health Out-
comes in Women Questionnaire; SMQ ¼ Sexual Modes Questionnaire; SQOL-F ¼ Iranian version of the Sexual Quality of Life questionnaireeFemale; SRC ¼ sexual response cycle; SSEI-SF ¼ Sexual Self-




























Table 2. Structural validity of the FSFI-19
Reference Methodology Outcome Rating Quality
Anis et al16 PCA 6-component structure Indeterminate Adequate
Bartula et al19 CFA 6 factors with item 14 removed: desire, arousal, lubrication, orgasm, satisfaction, pain Sufficient Very good
Bartula et al92 PCA 5 components: desire/arousal, lubrication, orgasm, satisfaction, pain Indeterminate Adequate
Baser et al20 EFA 5factors: desire/arousal, lubrication, orgasm, satisfaction, pain Indeterminate Adequate
Burri et al93 PCA FSFI-19: Unrotated PCA identified five components. Although the sixth component had a considerably
low eigenvalue, subsequent equamax rotation yielded the most consistent pattern of factor loadings
using a 6-component structure.
FSFI-LL: Unrotated PCA identified 3 components. Although the fourth and fifth components had
considerably low eigenvalues, subsequent equamax rotation yielded the most consistent pattern of
factor loadings using a 5-component structure.
Indeterminate Adequate
Burri et al93 CFA FSFI-19: The 6-factor solution was acceptable after allowing correlations between subscales and
between a number of items.
FSFI-LL: The 5-factor solution was acceptable after allowing correlations between subscales, and
between a number of items.
Sufficient Adequate
Burri et al24 PCA Unrotated PCA identified 5 components with eigenvalues higher than 1. Although the sixth component
had an eigenvalue <1, subsequent varimax rotation yielded the most consistent pattern of factor
loadings using a 6-component structure.
Indeterminate Adequate
Carpenter et al26 IRT After pruning based on violations of local independence, on discrimination, and difficulty parameters; 9
items remained of the 19 items of the FSFI-19.
Insufficient Adequate
Chang et al27 PCA 3 components were extracted and identified with eigenvalues greater than 1.03. These 3 components
accounted for a total of 87.10% of the variance. Component 1, with an initial eigenvalue of 13.74,
accounted for 72.32% of the explained variance. The 3 components were interpreted as “coitus” (15
items), “satisfaction” (2 items), and “desire” (2 items).
Indeterminate Adequate
Fakhri et al33 PCA The PCA yielded a best fitting, 5-component solution. All 5 components had eigenvalues of >1 and
accounted for 70% of the total variance.
Indeterminate Adequate
Fakhri et al33 CFA 6-factor structure showed inadequate fit (c2 ¼ 826.60; df ¼ 136; GFI ¼ 0.72; CFI ¼ 0.81; NNFI ¼ 0.63;
SRMR, 0.18; PNFI ¼ 0.63; RMSEA ¼ 0.15). 5-factor structure showed acceptable fit (c2 ¼ 304.07;
df ¼ 142; GFI ¼ 0.89; CFI ¼ 0.95; NNFI ¼ 0.94; SRMR, 0.08; PNFI ¼ 0.71; RMSEA ¼ 0.07).
Insufficient Adequate
Forbes et al38 PCA 5 components with eigenvalues >1. The 5 components were clearly defined as desire and subjective
arousal, lubrication, orgasm, satisfaction, and pain.
Indeterminate Adequate
Ghassamia et al39 PCA 5 components were extracted with eigenvalues >1. The examination of the scree plot suggested that 4
or 5 dimensions underlie the FSFI. The components were interpreted as “Sexual Response” (11 items),
“Sexual-related Pain” (3 items), “Sexual Desire” (2 items), “Sexual Satisfaction” (3 items).
Indeterminate Adequate
Heng et al41 PCA 3 components were extracted with eigenvalues >1. The first component comprised sexual arousal,
lubrication, and pain.The second component comprised orgasm and sexual satisfaction. Sexual desire
alone made the third component.
Indeterminate Adequate
Hevesi et al44 CFA 6-factor model had an acceptable fit (Satorra-Bentler c2 ¼ 490.924, df ¼ 137, P < .001; c2/df ¼ 3.583;
CFI ¼ 0.960; TLI ¼ 0.950; RMSEA ¼ 0.071; range ¼ 0.065-0.078). However, most intercorrelations
among the factors were very high.
A bi-factor model where each item was associated with a general factor and with its domain-specific

























Reference Methodology Outcome Rating Quality
P < .001; c2/df ¼ 2.217; CFI ¼ 0.983; TLI ¼ 0.976; RMSEA ¼ 0.049; range ¼ 0.041e0.057). It was
found that in the total sample most observed variance was attributable to the general sexual function
factor; whereas in the sexually active subsample most observed variance was attributable to the
specific factors.
Ismail et al45 PCA Among the women without type 2 diabetes, 3 components were extracted with eigenvalues >1: Sexual
desire/arousal, satisfaction, and pain. With the items in lubrication and orgasm domains loading on
both satisfaction and pain. Among the women with type 2 diabetes, 3 components were extracted
with eigenvalues >1: A component comprising of lubrication, orgasm, and pain; satisfaction, and
desire/arousal.
Indeterminate Adequate
Kalmbach et al47 CFA Bad model fit of six-factor model (c2 [137] ¼ 683.28, P < .001, CFI ¼ .91, TLI ¼ .88, RMSEA ¼ .07).
Adding latent variables describing whether an item was positively or negatively worded increased the
fit (c2 [118] ¼ 303.01, P < .001, CFI ¼ .97, TLI¼.95, RMSEA¼.04).
Insufficient Very good
Liu et al50 PCA 5 components were extracted with an eigenvalue >1, accounting for 77.57% of the total variance. The
first component consisted of a mixture of desire/arousal, and the rest were lubrication, orgasm,
satisfaction, and pain.
Indeterminate Adequate
Liu et al50 CFA A 6-factor model showed a bad fit (CMIN/DF ¼ 3.12, GFI ¼ .83, CFI ¼ .91, RMSEA ¼ .100). A 5-factor
model showed an acceptable fit (CMIN/DF ¼ 3.08, CFI ¼ .91, GFI ¼ .83, RMSEA ¼ .099). The 5
factors included desire/arousal, lubrication, orgasm, satisfaction, and pain.
Insufficient Adequate
Nowosielski et al58 PCA 5 components were extracted, accounting for 83.62% of the total variance. The components reflected
desire/arousal, lubrication, orgasm, satisfaction, and pain.
Indeterminate Adequate
Opperman et al59 CFA A first-order, 1 -factor model showed a bad fit: c2 (152, N ¼ 85) ¼ 664.45, P < .001 (c2/df ¼ 4.4;
GFI ¼ .55, TLI ¼ .34, CFI ¼ .41, and RMSEA ¼ .20). A first-order, 6-factor model with correlations
among factors showed a good fit: c2 (137, N ¼ 85) ¼ 178.96, P ¼ .009 (c2/df ¼ 1.3; GFI ¼ .83,
TLI ¼ .94, CFI ¼ .95, and RMSEA ¼ .06). A second-order, 6-factor model with 1 second-order factor
showed a decrement in fit compared to the first-order, 6-factor model: c2 (146, N ¼ 85) ¼ 199.72,
P ¼ .002 (c2/df ¼ 1.4; GFI ¼ .80, TLI ¼ .93, CFI ¼ .94, and RMSEA ¼ .066). A first-order, 5-factor
model showed a slight decrement in fit compared with the first-order and second-order, 6-factor
models: c2 (137, N ¼ 85) ¼ 215.89, P < .001 (c2/df ¼ 1.5; GFI ¼ .79, TLI ¼ .90, CFI ¼ .92, and
RMSEA ¼ .079). Delta c2 tests of differences indicated a better fit (Delta c2 [9, n ¼ 85] ¼ 21.62,
P < .05) of the first-order, 6-factor model (c2 [137, N ¼ 85] ¼ 178.96) vs the second-order, 6-factor
model (c2 [146,
N ¼ 85] ¼ 199.72), as well as a significantly better fit (Delta c2 [4, N ¼ 85] ¼ 37.79, P < .01) vs the
first-order, 5-factor model (c2 [142, N ¼ 85] ¼ 215.89).
Sufficient Inadequate
Rehman et al63 PCA 5-component structure: Desire, arousal, lubrication, orgasm, satisfaction and pain with eigenvalues
7.556, 3.457, 2.939, 2.926 and 0.633, respectively. These 5 components accounted for 92.164% of
the explained variance.
Indeterminate Adequate
Rillon-Tabil et al65 PCA 6-component structure Indeterminate Inadequate
Rosen et al2 CFA 5 factors: Desire/arousal, lubrication, orgasm, satisfaction, and pain; but desire/arousal was split into
2 factors due to theoretical considerations
Indeterminate Very good
Rosen et al2 PCA 5 components: Desire/arousal, lubrication, orgasm, satisfaction, and pain Indeterminate Inadequate





























Reference Methodology Outcome Rating Quality
4 components were extracted with eigenvalue >1. The first component was a mixture of arousal/
orgasm/satisfaction and the remaining 3 components were lubrication, pain, and desire. These 4
components accounted for a total of 75.01% of the explained variance
Takahashi et al74 EFA 5-factor structure found: desire/arousal, lubrication, orgasm, satisfaction, and pain Insufficient Adequate
Ter Kuile et al75 SCA 6-component structure explained 88.6% variance. Indeterminate Adequate
Ter Kuile et al75 PCA 6-component structure explained 81.6% variance. Indeterminate Adequate
Vallejo-Medina et al78 EFA 5-factor structure found with a clear ArousaleDesire fusion. Insufficient Adequate
Vallejo-Medina et al78 CFA A 6-factor uncorrelated factor model showed a bad fit (S-B c2 [df ¼ 146] ¼ 550.02, P < .001,
CFI ¼ .976, RMSEA ¼.076, AIC ¼ 258.02). A 6-factor correlated factor model showed a good fit
(S-B c2 [df ¼ 131] ¼ 209.31, P <. 001, CFI ¼ .995, RMSEA ¼ .036, AIC ¼ 52.68). A second-order,
6-factor model showed a good fit (S-B c2 [df ¼ 145] ¼ 353.60, P < .001, CFI ¼ .988,
RMSEA ¼ .055, AIC ¼ 63.60). A 5-factor correlated model showed a good fit (S-B c2 [df ¼
137] ¼ 338.86, P < .001, CFI ¼ .988, RMSEA ¼.056, AIC ¼ 64.86).
Sufficient Adequate
Wiegel et al82 PCA A PCA on a sample of sexually functional and dysfunctional women (n ¼ 272) showed a 5-component
structure: desire/arousal, lubrication, orgasm, pain, and satisfaction.
A PCA in women with sexual dysfunction resulted in 4 components with eigenvalues >1 and 1
component with eigenvalue of 0.98. The 4 components were interpreted as pain, orgasm, lubrication,
desire/arousal/satisfaction. When taking the fifth component into account, they were interpreted as
desire/arousal, lubrication, orgasm, pain, and satisfaction.
A PCA in women without sexual dysfunction resulted in 5 components with eigenvalues >1, which were
interpreted as desire/arousal, orgasm/arousal, lubrication, satisfaction, and pain.
A PCA of the combined group (dysfunctional and non-dysfunctional; n ¼ 527) resulted in 5 components
with eigenvalues >1, which were interpreted as: desire/arousal, orgasm/arousal, lubrication,
satisfaction, and pain.
Indeterminate Adequate
Witting et al83 EFA 4 factors had an eigenvalue > 1. The fifth factor had an eigenvalue of 0.84 for Twin 1 group and 0.85 for
Twin 2 group.The sixth factor had an eigenvalue of 0.57 and 0.62, respectively. After exploring 4-, 5-,
and 6-factor solutions, it was decided to use the 6-factor solution due to interpretability. The 6-factor
solution explained 76.6% of the variance for Twin 1, whereas a general factor only explained 48.6%.
The corresponding figures for Twin 2 were 75.3% and 47.0%, respectively. This suggested that a
1-factor model was not adequate.
Indeterminate Adequate
Witting et al83 CFA A six-factor model in the Twin 1 group showed a bad fit (c2 [df ¼ 137] ¼ 789.03, GFI ¼ .924;
NFI ¼ .956, RMSEA ¼ .067, AIC 895.08). The results for Twin 2 were similar.
Insufficient Adequate
Wolpe et al84 PCA 2-component structure was found with the first component explaining 76.66% of variance, and the
second component explaining 6.16% of variance.
Indeterminate Adequate
Wylomanski et al85 EFA 6-factor structure was found, explaining 71.4% of variance. Indeterminate Adequate
Wylomanski et al85 CFA 6-factor model did not fit the data. The model was adjusted based on modification indices, adding
covariance between error terms of 4-item pairs: 7e10, 15e16, 3e4 and 8e9. Each pair of items
included a similar content. This adjusted model showed a good fit (Q ¼ 2.8, CFI ¼ 0.98,
RMSEA ¼ 0.06 and SRMR ¼ 0.03).
Insufficient Adequate
AIC ¼ akaike information criterion; CFA ¼ confirmatory factor analysis; CFI ¼ comparative fit index; EFA ¼ exploratory factor analysis; FSFI ¼ Female Sexual Function Index; GFI ¼ goodness of fit index;
NFI ¼ normed fit index; NNFI ¼ non-normed fit index; PCA ¼ principal component analysis; PNFI ¼ parsimony normed fit index; RMSEA ¼ root mean square error of approximation; S-B ¼ Satorra-Bentler;






















Table 3. Test-retest reliability of the FSFI
Reference Coefficient Total score DE AR LU OR SA PA Rating Quality
FSFI-19
Anis et al16 Correlation .98 .92 .98 .97 .98 .96 .97 Sufficient Doubtful
Bartula et al19 Correlation .86 .82 .78 .80 .76 .75 Sufficient Doubtful
Borello-France et al22 ICC .91 .84 .86 .82 .90 .79 .88 Sufficient Adequate
Chang et al27 Correlation .69 Insufficient Doubtful
Fakhri et al. (2012) 33 ICC .77 .84 .78 .86 .82 .79 .73 Sufficient Adequate
Filocamo et al36 Correlation .95 .93 .93 .95 .92 .92 .93 Sufficient Doubtful
Ghassamia et al39 Correlation .82 .66 .72 .78 Sufficient Doubtful
Liu et al50 Correlation .84 .68 .83 Sufficient Doubtful
Nowosielski et al58 ICC day 7 .83 .83 .89 .85 .88 .87 .80 Sufficient Adequate
ICC day 28 .75 .80 .86 .80 .81 .78 .73
Rehman et al63 ICC .99 1.00 1.00 .99 .98 .99 1.00 Sufficient Doubtful
Rillon-Tabil et al65 Correlation .99 Sufficient Doubtful
Rosen et al2 Correlation .88 .83 .85 .86 .80 .83 .79 Sufficient Doubtful
Ryding et al68 Correlation .77 - .95 .67 -.89 .62 - .90 .35 - .85 .65 - .86 .65 - .86 .10 - .90 Insufficient Doubtful
Sidi et al70 Correlation .87 .77 .95 .97 .95 .86 Sufficient Doubtful
Sun et al73 Correlation .80 - .86 .72 - .85 .78 - .95 .74 - .93 .85 - .89 .80 - .86 .69 - .90 Sufficient Doubtful
Takahashi et al74 ICC .73 e 1.00 .73 e 1.00 .73 e 1.00 .73 e 1.00 .73 e 1.00 .73 e 1.00 Sufficient Inadequate
Ter Kuile et al75 Correlation .93 .72 .85 .82 .71 .90 .97 Sufficient Inadequate
Verit et al80 Correlation .90e.92 .79 - .81 .85 - .87 .85 - .88 .83 - .87 .83 - .85 .89 Sufficient Doubtful
Wolpe et al84 ICC .94 Sufficient Adequate
Wylomanski et al85 ICC .99 .97 .99 .97 .96 .89 .99 Sufficient Adequate
Zachariou et al86 Correlation .91 Sufficient Doubtful
FSFI-6
Isidori et al4 Correlation .95 Sufficient Doubtful
Lee et al89 ICC .61 Insufficient Adequate
FSFI-BC (34 items)
Bartula et al92 Correlation .72 - .88 .71 - .72 .63 - .85 .86 .77 - .80 Sufficient Doubtful



























Table 4. Criterion validity
Reference Instrument AUC Cutoff Sensitivity Specificity PPV PNV Rating Quality
FSFI-19
Anis et al16 FSD diagnosis .99 .97 .93 Sufficient Very good
Fakhri et al33 FSD diagnosis .91 .82 .86 Sufficient Very good
Gerstenberger et al40 HSDD diagnosis .70 - .97 .84 - .97 Sufficient Very good
Ma et al51 FSD diagnosis Total FSFI 23.45 .67 .73 Sufficient Very good
Low desire .73 <2.8 .55 .78
Arousal disorder .74 <3.16 .62 .77
Lubrication disorder .85 <4.06 .86 .70
Orgasm disorder .85 <3.9 .83 .74
Sexual pain .79 <3.9 .65 .81
Nowosielski et al58 FSD diagnosis .93 .87 .83 .86 Sufficient Very good
Ryding et al68 HSDD diagnosis .96 .97 Indeterminate Very good
Sidi et al70 FSD diagnosis .99 .99 .97 Sufficient Very good
Ter Kuile et al75 FSD diagnosis .98 .95 .92 .96 .89 Sufficient Adequate
Wiegel et al82 FSD diagnosis .90 26.55 .88 - .89 .71 - .73 Sufficient Very good
Zachariou et al86 FSD diagnosis .86 .72 .93 Sufficient Doubtful
FSFI-6
Isidori et al4 FSD diagnosis .98 19 .96 .91 .95 .93 Sufficient Very good
Lee et al89 FSD diagnosis .95 .90 .86 Sufficient Very good
AUC ¼ area under the curve; FSD ¼ female sexual disorder; FSFI ¼ Female Sexual Function Index; HSDD ¼ hypoactive sexual desire disorder.
654 Neijenhuijs et alMethodologic quality was rated as “adequate”14,19,48,92 or
“doubtful”.2,58,68 The “doubtful” ratings were due to lack of in-
formation on the measurement properties of the comparator
instrument.
2 studies of “adequate” quality14,19 and 3 studies of “doubtful”
quality2,68,76 reported low correlation coefficients that were rated
as sufficient. 2 studies of “adequate” quality,48,92 and 1 study of
“doubtful” quality 58 reported multiple correlation coefficients
>0.30 and were rated as insufficient. None of the studies that
investigated the FSFI-64,88e91 reported on divergent validity.
Criterion Validity
10 studies reported on criterion validity of the FSFI-19 using
the gold standard of FSD or HSDD diag-
nosis16,33,40,51,58,68,70,75,82,86 (Table 4). Methodologic quality
was rated as “very good”,16,33,40,51,58,68,70,82 as “adequate”,75 or
as “doubtful”.86 The “doubtful” rating was due to a small sample
size (“other flaws” in COSMIN methodologic quality).86 1 study
did not report an area under the curve (AUC) and was thus rated
indeterminate.68 All remaining studies reported AUC values that
were rated as sufficient.
2 studies reported on criterion validity of the FSFI-6 using
FSD diagnosis as the gold standard4,89 (Table 4). Methodologic
quality was rated as “very good” for both studies. Both studies
reported AUC values that were rated as sufficient.Data Synthesis
The synthesized ratings of the measurement properties across all
studies can be found in Table 5. The evidence of structural validityof the FSFI-19was rated as inconsistent, because 6-factor, 5-factor,
and other factor structures were reported. The evidence was
evaluated as low quality because of this inconsistency, as well as a
risk of bias because many studies reported a principle component
analysis (PCA) instead of an exploratory or confirmatory factor
analysis. The evidence of internal consistency of the FSFI-19 was
rated as sufficient but of moderate quality, due to 15.8% (n¼ 6) of
studies reporting insufficient internal consistency.
The evidence of test-retest reliability of the FSFI-19 was rated
as sufficient but of low quality, due to 13.0% (n ¼ 3) of studies
reporting insufficient test-retest reliability, as well as risk of bias
as many studies reported Pearson correlation instead of the
intraclass correlation coefficient. The use of Pearson correlations
are problematic, because they do not control for systematic error
variance, which is a product of measuring the same individual
twice. The intraclass correlation coefficient controls for this
systematic error variance, and without this control, test-retest
reliability may be overestimated.95,96 The evidence of construct
validity (hypothesis testing) of the FSFI-19 was rated as incon-
sistent with moderate quality, because 28.6% (n ¼ 18) of studies
reported insufficient values. The evidence of criterion validity of
the FSFI-19 was rated as sufficient with high quality. The evi-
dence of measurement error and responsiveness of the FSFI-19
were rated as indeterminate, because no data were reported on
these measurement properties.
Evidence of structural validity of the FSFI-6 was rated as
indeterminate because no data were reported on this measurement
property. The evidence of internal consistency of the FSFI-6 was
rated as indeterminate, as evidence for unidimensionality wasJ Sex Med 2019;16:640e660
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Measurement Properties of the FSFI 655missing. The evidence of line number test-retest reliability of the
FSFI-6 was rated as inconsistent and of low quality, due to risk of
bias because only 2 studies reported on test-retest reliability, of
which 1 study was of doubtful methodologic quality. The evidence
of construct validity (hypothesis testing) of the FSFI-6 was rated as
inconsistent with very low quality, because there were as many
studies reporting sufficient (50%) as insufficient values (50%), as
well as a risk of bias due tomethodologic quality of the studies. The
evidence of criterion validity of the FSFI-6 was rated as sufficient
and of moderate quality, as the evidence was based on only 2
studies. The evidence of measurement error and responsiveness of
the FSFI-6 were rated as indeterminate, because no data were re-
ported on these measurement properties.DISCUSSION
This systematic review investigated the evidence of the mea-
surement properties of the FSFI-192 and FSFI-6.4 Concerning
the FSFI-19, the evidence on internal consistency was sufficient
and of moderate quality. The evidence on test-retest reliability
was also sufficient but of low quality due to some inconsistencies
and many studies not using the intraclass correlation. The evi-
dence on criterion validity was also sufficient and of high quality.
The evidence on structural validity was inconsistent and of low
quality. Studies found either evidence for the theorized 6-factor
structure, a 5-factor structure (with a merging of desire and
arousal) or structures with <5 factors. Evidence on construct
validity was inconsistent and of moderate quality. No data was
found on measurement error and responsiveness.
Concerning the FSFI-6, the evidence on criterion validity was
sufficient and of moderate quality. Evidence on reliability wasJ Sex Med 2019;16:640e660inconsistent with low quality of evidence, due to a high risk of
bias. Evidence on construct validity was inconsistent with very
low quality of evidence, due to as many studies reporting suffi-
cient as insufficient values as well as a risk of bias due to
methodologic quality. The evidence of structural validity, inter-
nal consistency, measurement error, and responsiveness were
rated as indeterminate.
Regarding the structural validity of the FSFI-19, there was
more evidence against than in favor of the hypothesized 6-factor
structure. This is in line with the revisions made in the DSM-5
to the model of FSD.5 Whereas only 2 articles showed direct
support for a 5-factor structure,33,50 12 more studies showed
indirect support for a 5-factor solution through use of
PCAs.2,20,24,33,38,39,50,58,63,82,92,93 However, other PCAs resul-
ted in other factor structures: 4 factors,73,82,83 3 factors,27,41,45
or 2 factors.84 Based on the wide range of reported factor
structures, it may be that the factor structure of the FSFI-19 is
different for different subgroups or nationalities. In fact, some
studies investigated factor structures in subgroups, and results
suggest that there are different factor structures of the FSFI-19
among women with FSD and women without FSD.44,82 Un-
fortunately, neither study performed a test of measurement
invariance, and, as such, there is no direct evidence for this
hypothesis. Such differences in factor structure in different
subgroups may be related to a number of theoretical positions.
For one, differing motivations for sex for women with arousal
disorder vs without arousal disorder 97 may suggest that arousal
and desire may be a singular motivation (ie, a singular construct)
for women without arousal disorder, but not for women with an
arousal disorder. Furthermore, the position that FSD represents
a spectrum of disorders with extensive overlap98e100 implies that
the constructs measured by the FSFI-19 may be different for
women suffering from differing (yet overlapping) sexual
disorders.
Nevertheless, based on this systematic review, we conclude
that the use of the 6 subscales may not be valid in all patient
groups. Instead, we see compelling evidence to merge the sub-
scales of arousal and desire. For confirming whether these sub-
scales should be merged, and whether the constructs measured by
the FSFI-19 are different for subpopulations of women, a
large-scale validation study focusing on testing measurement
invariance across patient subgroups and nationalities, as well as
multiple factor structures through use of confirmatory factor
analyses is needed. In the meantime we recommend that, to
ensure valid interpretation of their results, researchers perform
and report on structural validity of the FSFI-19 when presenting
the results of their studies.
Although we rated the evidence on internal consistency as
sufficient for the FSFI-19, it needs to be noted that unidimen-
sionality of the subscales is a prerequisite or interpreting their
internal consistency. As the structural validity of the FSFI-19 is
shaky at best, our rating of the evidence on internal consistency is
mostly intended as an interpretation for the subscales that are
656 Neijenhuijs et alfound as being unidimensional in most analyses: lubrication,
satisfaction, and pain.
With respect to the structural validity of the FSFI-6, validation
studies investigating the unidimensional nature of the instrument
are of importance, because no studies investigated this mea-
surement property. The FSFI-6 results in 1 score representing
FSD in general, and it is crucial to determine whether all items
represent the construct of FSD in a unidimensional manner.
However, structural validity of the FSFI-6 is likely not so
straightforward: because the 6 best-performing items of the FSFI-
19 were selected from each domain, any and all overlap of
constructs of the subscales of the FSFI-19 will also be represented
in the FSFI-6. Furthermore, as the FSFI-6 is a composite of
multiple constructs, it is unlikely to be unidimensional because it
is based on a formative model instead of a reflective model. This
raises issues with the interpretation of the FSFI-6 total score,
because it may not reflect 1 general construct of FSD. For a total
score of a multidimensional instrument, it is unclear what exact
construct is represented by the total score.
The evidence on internal consistency of the FSFI-6 cannot yet
be determined, because the unidimensionality (a prerequisite for
internal consistency) has not yet been determined. However, if
the FSFI-6 is found to be unidimensional, internal consistency is
likely to be rated as sufficient, because 3 studies of very good
quality found values of Cronbach’s a that would be rated as
sufficient.
Research into measurement error and responsiveness is
necessary as well. With the high use of the FSFI-19 and FSFI-6
in clinical practice and clinical research, it is of importance to
know which change can be distinguished from measurement
error. To further the knowledge, we recommend that researchers
perform test-retest reliability studies to calculate the limits of
agreement or smallest detectable change.95 Furthermore, an
anchor-based study is recommended to determine the minimal
important change to be able to interpret the limits of agreement
or smallest detectable change.101
Combining the concerns surrounding structural validity,
inconsistent findings on multiple measurement properties, the
low quality of many of the included studies, and the missing
information on multiple measurement properties; questions are
raised on the validity and reliability of the FSFI-19 and FSFI-6 as
measures of FSD. The content validity of the FSFI-19 has been
challenged previously,102 where the FSFI-19 was described as a
measure of vaginal intercourse, and not FSD. Combining con-
cerns regarding content validity, as well as our concerns regarding
structural validity, it is unclear whether the FSFI measures FSD,
or a selection of symptoms related to FSD. Regardless of these
concerns, evidence for criterion validity is strong. Pragmatically,
the FSFI is a good screening tool for the current definition of
FSD. However, from a psychometric point of view, the above
concerns are serious. Given the high frequency of use of both the
FSFI-19 and the FSFI-6 in clinical screening for FSD, as well as
an outcome measure for clinical trials, it is of importance thatmore research is performed into the measurement properties and
content validity.
A limitation of this review is that we did not investigate
content validity. Content validity needs to be established before
other measurement properties can be evaluated.6 A future
investigation of content validity is warranted. Another limitation
of this review is the use of a precise rather than a sensitive search
filter regarding measurement properties. The sensitive filter was
developed to capture every relevant hit, at the expense of
capturing more false-positive search hits. Meanwhile the specific
filter was developed to capture as many relevant hits, while
decreasing the number of false-positive search hits. The sensi-
tivity of the precise filter was 93% in a random set of PubMed
records, whereas the sensitivity of the sensitive search filter was
97%.12 The use of the precise filter was a pragmatic choice over
the available sensitive filter because the initial search encom-
passed 39 PROMs (including the FSFI-19 and FSFI-6), and the
sensitive filter would provide too many hits for feasible screening.
The possibility remains that the precise filter missed some vali-
dation studies of the FSFI-19 and FSFI-6.CONCLUSIONS
Based on this systematic review,we conclude thatwith respect to
internal consistency, reliability, and criterion validity, the FSFI-19
meets psychometric criteria, but has not been shown to meet
psychometric criteria for structural validity, measurement error,
construct validity, and responsiveness. Evidence on structural
validity suggests amerging of the subscales arousal and desire. Such
a merging of subscales has consequences for the interpretation of
the FSFI-19 in both clinical practice and research. To investigate
this possible adjustment to the FSFI-19, as well as the suggestion
that factor structures may be population-dependent; a large-scale
cross-cultural study design or an individual patient data meta-
analysis, applying Confirmatory Factor Analysis, measurement
invariance tests, and calculating the limits of agreement and
smallest detectable change, is recommended.
The FSFI-6 meets psychometric criteria with respect to cri-
terion validity. Structural validity, internal consistency, reli-
ability, measurement error, construct validity, and responsiveness
require further research. Most importantly for future research is
determining the unidimensionality of the FSFI-6. Regardless of
these concerns, evidence for criterion validity is strong for both
the FSFI-19 and FSFI-6, and pragmatically, they are good
screening tools for the current definition of FSD.ACKNOWLEDGMENTS
We thank Margot Veeger for help with the screening pro-
cedures. We thank Anja van der Hout, Heleen Melissant, and
Evalien Veldhuijzen for help with the data extraction procedures.
CorrespondingAuthor: IrmaM.Verdonck-deLeeuw, PhD,Vrije
Universiteit Amsterdam, Department of Clinical, Neuro- andJ Sex Med 2019;16:640e660
Measurement Properties of the FSFI 657Developmental Psychology, The Netherlands. Tel: þ31 20 444
0931; Fax: þ31 20 444 3688; E-mail: IM.Verdonck@vumc.nl
Conflicts of Interest: The authors report no conflicts of interest.
Funding: This work was supported by the Dutch Cancer Society
[grant number VUP 2014-7202].
STATEMENT OF AUTHORSHIP
Category 1
(a) Conception and DesignJ SeKoen I. Neijenhuijs; Neil K. Aaronson; Mogens Groenvold;
Bernhard Holzner; Caroline B. Terwee; Pim Cuijpers; Irma M.
Verdonck-de Leeuw(b) Acquisition of Data
Koen I. Neijenhuijs; Nienke Hooghiemstra; Karen Holtmaat(c) Analysis and Interpretation of Data
Koen I. Neijenhuijs; Nienke Hooghiemstra; Karen HoltmaatCategory 2
(a) Drafting the Article
Koen I. Neijenhuijs(b) Revising It for Intellectual Content
Nienke Hooghiemstra; Karen Holtmaat; Neil K. Aaronson;
Mogens Groenvold; Bernhard Holzner; Caroline B. Terwee; Pim
Cuijpers; Irma M. Verdonck-de LeeuwCategory 3
(a) Final Approval of the Completed Article
Koen I. Neijenhuijs; Nienke Hooghiemstra; Karen Holtmaat; Neil
K. Aaronson; Mogens Groenvold; Bernhard Holzner; Caroline B.
Terwee; Pim Cuijpers; Irma M. Verdonck-de LeeuwREFERENCES
1. Basson R, Berman J, Burnett A, et al. Report of the inter-
national consensus development conference on female sexual
dysfunction: Definitions and classifications. J Urol 2000;
163:888-893.
2. Rosen R, Brown C, Heiman J, et al. The Female Sexual
Function Index (FSFI): A multidimensional self-report instru-
ment for the assessment of female sexual function. J Sex
Marital Ther 2000;26:191-208.
3. Locke HJ, Wallace KM. Short marital-adjustment and pre-
diction tests: Their reliability and validity. Marriage and
Family Living 1959;21:251-255.
4. Isidori AM, Pozza C, Esposito K, et al. Development and
validation of a 6-item version of the female sexual function
index (FSFI) as a diagnostic tool for female sexual dysfunc-
tion. J Sex Med 2010;7:1139-1146.
5. American Psychiatric Association. DSM-5 Task Force. Diag-
nostic and Statistical Manual of Mental Disorders: DSM-5.
Philadelphia: American Psychiatric Association; 2013.
6. Prinsen CAC, Mokkink LB, Bouter LM, et al. COSMIN
guideline for systematic reviews of patient-reported outcome
measures. Qual Life Res 2018;27:1147-1157.
7. Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study
reached international consensus on taxonomy, terminology,x Med 2019;16:640e660and definitions of measurement properties for health-related
patient-reported outcomes. J Clin Epidemiol 2010;63:737-
745.
8. van der Hout A, van Uden-Kraan CF, Witte BI, et al. Efficacy,
cost-utility, and reach of an eHealth self-management appli-
cation “Oncokompas” that facilitates cancer survivors to
obtain optimal supportive care: Study protocol for a ran-
domized controlled trial. Trials 2017;18:228.
9. Lubberding S, van Uden-Kraan CF, Te Velde EA, et al.
Improving access to supportive cancer care through an
eHealth application: A qualitative needs assessment among
cancer survivors. J Clin Nurs 2015;24:1367-1379.
10. Jansen F, van Uden-Kraan CF, Van Zwieten V, et al. Cancer
survivors’ perceived need for supportive care and their atti-
tude towards self-management and eHealth. Support Care
Cancer 2015;23:1679-1688.
11. Duman-Lubberding S, van Uden-Kraan CF, Jansen F, et al.
Feasibility of an eHealth application “OncoKompas” to
improve personalized survivorship cancer care. Supportive
Care Cancer 2016;24:2163-2171.
12. Terwee CB, Jansma EP, Riphagen II, et al. Development of a
methodological PubMed search filter for finding studies on
measurement properties of measurement instruments. Qual
Life Res 2009;18:1115-1123.
13. Mokkink LB, de Vet HCW, Prinsen CAC, et al. COSMIN Risk of
Bias checklist for systematic reviews of Patient-Reported
Outcome Measures. Qual Life Res 2018;27:1171-1179.
14. Achimas-Cadariu P, Irimie A, Iancu M, et al. Identification and
validation of quality of life measures in a population of women
with premalignant and malignant pathology at childbearing
age. J Cogn Behav Psychother 2013;13:409-420.
15. Ahmed MR, Shaaban MM, Meky HK. Assessment of sexually
related personal distress accompanying premenopausal sex-
ual dysfunction with an Arabic version of the Female Sexual
Distress Scale. Int J Gynecol Obstet 2017;139:65-70.
16. Anis T, Gheit AS. Arabic translation of Female Sexual Function
Index and validation in an Egyptian population. J Sex Med
2011;8:3370-3378.
17. Aydin S, Onaran OI, Topalan K, et al. Development and vali-
dation of Turkish version of The Female Sexual Distress
ScaleeRevised. Sex Med 2016;4:E43-E50.
18. Azimi Nekoo E, Burri A, Ashrafti F, et al. Psychometric
properties of the Iranian version of the Female Sexual Distress
Scale-Revised in women. J Sex Med 2014;11:995-1004.
19. Bartula I, Sherman KA. The Female Sexual Functioning Index
(FSFI): Evaluation of acceptability, reliability, and validity in
women with breast cancer. Support Care Cancer 2015;
23:2633-2641.
20. Baser RE, Li YL, Carter J. Psychometric validation of the
female sexual function index (FSFI) in cancer survivors.
Cancer 2012;118:4606-4618.
21. Bloemendaal LBA, Laan ETM. The psychometric properties
of the Sexual Excitation/Sexual Inhibition Inventory for
Women (SESII-W) within a Dutch population. J Sex Res
2015;52:69-82.
658 Neijenhuijs et al22. Borello-France D, Dusi J, O’Leary M, et al. Test-retest reli-
ability of the Urge-Urinary Distress Inventory and Female
Sexual Function Index in women with multiple sclerosis. Urol
Nurs 2008;28:30-35.
23. Bornefeld-Ettmann P, Steil R, Hoefling V, et al. Validation of
the German version of the Sexual Self-Esteem Inventory for
Women and its application in a sample of sexually and
physically abused women. Sex Roles 2018;79:109-122.
24. Burri A, Porst H. Preliminary validation of a German version
of the Sexual Complaints Screener for Women in a female
population sample. Sex Med 2018;6:123-130.
25. Carpenter JS, Reed SD, Guthrie KA, et al. Using an FSDS-R
item to screen for sexually related distress: A MsFLASH
Analysis. Sex Med 2015;3:7-13.
26. Carpenter JS, Jones SMW, Studts CR, et al. Female Sexual
Function Index Short Version: A MsFLASH Item Response
Analysis. Arch Sex Behav 2016;45:1897-1905.
27. Chang S-R, Chang T-C, Chen K-H, et al. Developing and
validating a Taiwan version of the Female Sexual Function
Index for pregnant women. J Sex Med 2009;6:1609-1616.
28. Clayton A, Segraves R, Leiblum S, et al. Reliability and validity
of the Sexual Interest and Desire Inventory-Female (SIDI-F), a
scale designed to measure severity of female hypoactive
sexual desire disorder. J Sex Marital Ther 2006;32:115-135.
29. Clayton A, Goldmeier D, Nappi R, et al. Validation of the
Sexual Interest And Desire Inventory-Female in hypoactive
sexual desire disorder. J Sex Med 2010;7:3918-3928.
30. Constantine ML, Pauls RN, Rogers RR, et al. Validation of a
single summary score for the Prolapse/Incontinence Sexual
Questionnaire-IUGA revised (PISQ-IR). Int Urogynecol J
2017;28:1901-1907.
31. DeRogatis LR, Allgood A, Auerbach P, et al. Validation of a
Women’s Sexual Interest Diagnostic IntervieweShort Form
(WSID-SF) and a Daily Log of Sexual Activities (DLSA) in
postmenopausal women with hypoactive sexual desire dis-
order. J Sex Med 2010;7:917-927.
32. Eaton A, Baser R, Seidel B, et al. Validation of clinical tools for
vaginal and vulvar symptom assessment in cancer patients
and survivors. J Sex Med 2017;14:144-151.
33. Fakhri A, Pakpour A, Burri A, et al. The Female Sexual
Function Index: Translation and validation of an Iranian
version. J Sex Med 2012;9:514-523.
34. Farkas B, Tiringer I, Farkas N, et al. Hungarian language
validation of the Pelvic Organ Prolapse/Incontinence Sexual
Questionnaire, IUGA-Revised (PISQ-IR). Int Urogynecol J
2016;27:1831-1836.
35. Ferguson SE, Urowitz S, Massey C, et al. Confirmatory
factor analysis of the sexual adjustment and body image
scale in women with gynecologic cancer. Cancer 2012;
118:3095-3104.
36. Filocamo MT, Serati M, Marzi VL, et al. The Female Sexual
Function Index (FSFI): Linguistic validation of the Italian
version. J Sex Med 2014;11:447-453.
37. Flynn KE, Reeve BB, Lin L, et al. Construct validity of the
PROMIS sexual function and satisfaction measures in pa-
tients with cancer. Health Qual Life Outcomes 2013;11:1.38. Forbes MK, Baillie AJ, Schniering CA. Critical flaws in the
Female Sexual Function Index and the International Index of
Erectile Function. J Sex Res 2014;51:485-491.
39. Ghassamia M, Asghari A, Shaeiri MR, et al. Validation of
psychometric properties of the Persian version of the Female
Sexual Function Index. Urol J 2013;10:878-885.
40. Gerstenberger E, Rosen R, Brewer J, et al. Sexual Desire and
the Female Sexual Function Index (FSFI): A sexual desire
cutpoint for clinical interpretation of the FSFI in women with
and without hypoactive sexual desire disorder. J Sex Med
2010;7:3096-3103.
41. Heng YS, Sidi H, Jaafar NRN, et al. Phases of female sexual
response cycle among Malaysian women with Infertility: A
factor analysis study. Asia-Pacific Psychiatry 2013;5:50-54.
42. Herbenick D, Reece M. Development and validation of
the female genital self-image scale. J Sex Med 2010;
7:1822-1830.
43. Herbenick D, Schick V, Reece M, et al. The Female Genital
Self-Image Scale (FGSIS): Results from a Nationally Repre-
sentative Probability Sample of Women in the United States.
J Sex Med 2011;8:158-166.
44. Hevesi K, Meszaros V, Kovi Z, et al. Different characteristics
of the Female Sexual Function Index in a sample of sexually
active and inactive women. J Sex Med 2017;14:1133-1141.
45. Ismail A, Bau R, Sidi H, et al. Factor analysis study on sexual
responses in women with Type 2 diabetes mellitus.
Comprehensive Psychiatr 2014;55:S34-S37.
46. Jing L-W, Zhang C, Jin F, et al. Development of a quality of
sexual life questionnaire for breast cancer survivors in Main-
land China. Med Sci Monitor 2018;24:4101-4112.
47. Kalmbach D, Ciesla J, Janata J, et al. The validation of the
Female Sexual Function Index, Male Sexual Function Index,
and Profile of Female Sexual Function for use in healthy
young adults. Arch Sex Behav 2015;44:1651-1662.
48. Likes WM, Stegbauer C, Hathaway D, et al. Use of the female
sexual function index in women with vulvar intraepithelial
neoplasia. J Sex Marital Ther 2006;32:255-266.
49. Liu B, Su M, Zhan H, et al. Adding a sexual dysfunction
domain to UPOINT system improves association with
symptoms in women with interstitial cystitis and bladder pain
syndrome. Urology 2014;84:1308-1313.
50. Liu H, Yu J, Chen Y, et al. Sexual function in cervical cancer
patients: Psychometric properties and performance of a
Chinese version of the Female Sexual Function Index. Eur J
Oncol Nurs 2016;20:24-30.
51. Ma J, Pan L, Lei Y, et al. Prevalence of female sexual
dysfunction in urban Chinese women based on cutoff scores
of the Chinese version of the Female Sexual Function Index: A
preliminary study. J Sex Med 2014;11:909-919.
52. Meston C. Validation of the Female Sexual Function Index
(FSFI) in women with female orgasmic disorder and in women
with hypoactive sexual desire disorder. J Sex Marital Ther
2003;29:39-46.
53. Meston C, Trapnell P. Development and validation of a five-
factor sexual satisfaction and distress scale for women: TheJ Sex Med 2019;16:640e660
Measurement Properties of the FSFI 659Sexual Satisfaction Scale for Women (SSS-W). J Sex Med
2005;2:66-81.
54. Mestre M, Lleberia J, Pubill J, et al. Spanish version of the
Pelvic Organ Prolapse/Urinary Incontinence Sexual Ques-
tionnaire IUGA-Revised (PISQ-IR): Transcultural validation.
Int Urogynecol J 2017;28:1865-1873.
55. Mohammadi K, Rahnama P, Montazeri A, et al. The Multiple
Sclerosis Intimacy and Sexuality Questionnaire-19: Reliability,
validity, and factor structure of the Persian version. J Sex
Med 2014;11:2225-2231.
56. Mohammed G-K, Hassan H. Validity and reliability of the
Arabic version of the Female Genital Self-Image Scale. J Sex
Med 2014;11:1193-1200.
57. Nimbi F, Tripodi F, Simonelli C, et al. Sexual Modes Ques-
tionnaire (SMQ): Translation and psychometric properties of
the Italian version of the Automatic Thought Scale. J Sex
Med 2018;15:410-415.
58. Nowosielski K, Wróbel B, Sioma-Markowska U, et al. Devel-
opment and validation of the Polish version of the Female
Sexual Function Index in the Polish population of females.
J Sex Med 2013;10:386-395.
59. Opperman EA, Benson LE, Milhausen RR. Confirmatory fac-
tor analysis of the Female Sexual Function Index. J Sex Res
2013;50:29-36.
60. Pakpour A, Zeidi I, Saffari M, et al. Psychometric properties of
the Iranian version of the Sexual Quality of Life Scale among
women. J Sex Med 2013;10:981-989.
61. Pakpour A, Zeidi I, Ziaeiha M, et al. Cross-cultural adaptation
of the Female Genital Self-Image Scale (FGSIS) in Iranian
female college students. J Sex Res 2014;51:646-653.
62. Pascoal P, Alvarez M-J, Pereira C, et al. Development and
Initial Validation of the Beliefs About Sexual Functioning
Scale: A gender invariant measure. J Sex Med 2017;
14:613-623.
63. Rehman K, Asif Mahmood M, Sheikh S, et al. The Female
Sexual Function Index (FSFI): Translation, validation, and
cross-cultural adaptation of an Urdu version “FSFI-U.” Sex
Med 2015;3:244-250.
64. Rellini A, Meston C. The sensitivity of event logs, self-
administered questionnaires and photoplethysmography to
detect treatment-induced changes in female sexual arousal
disorder (FSAD) diagnosis. J Sex Med 2006;3:283-291.
65. Rillon-Tabil N, Malong C,Vicera J, et al. Translation and validity
of the female sexual function index Filipino version (FSFI-Fil).
Philippine J Intern Med 2013;51.
66. Rogers R, Rockwood T, Constantine M, et al. A new measure
of sexual function in women with pelvic floor disorders (PFD):
The Pelvic Organ Prolapse/Incontinence Sexual Question-
naire, IUGA-Revised (PISQ-IR). Int Urogynecol J 2013;
24:1091-1103.
67. Rosen R, Bachmann G, Reese J, et al. Female Sexual Well-
Being Scale (FSWB Scale): Development and psychometric
validation in sexually functional women. J Sex Med 2009;
6:1297-1305.J Sex Med 2019;16:640e66068. Ryding E, Blom C. Validation of the Swedish version of the
Female Sexual Function Index (FSFI) in Women with Hypo-
active Sexual Desire Disorder. J Sex Med 2015;12:341-349.
69. Selcuk S, Kucukbas M, Cam C, et al. Validation of the Turkish
version of the Sexual Health Outcomes in Women Ques-
tionnaire (SHOW-Q) in Turkish-speaking women. Sex Med
2016;4:e89-e94.
70. Sidi H, Abdullah N, Puteh S, et al. The Female Sexual Function
Index (FSFI): Validation of the Malay version. J Sex Med
2007;4:1642-1654.
71. Sills T, Wunderlich G, Pyke R, et al. The Sexual Interest and
Desire Inventory-Female (SIDI-F): Item response analyses of
data from women diagnosed with hypoactive sexual desire
disorder. J Sex Med 2005;2:801-818.
72. Stephenson K, Toorabally N, Lyons L, et al. Further validation
of the Female Sexual Function Index: Specificity and associ-
ations with clinical interview data. J Sex Marital Ther 2016;
42:448-461.
73. Sun X, Li C, Jin L, et al. Development and validation of Chi-
nese version of Female Sexual Function Index in a Chinese
population—A pilot study. J Sex Med 2011;8:1101-1111.
74. Takahashi M, Inokuchi T,Watanabe C, et al. The Female Sexual
Function Index (FSFI): Development of a Japanese version.
J Sex Med 2011;8:2246-2254.
75. Ter Kuile M, Brauer M, Laan E. The Female Sexual Function
Index (FSFI) and the Female Sexual Distress Scale (FSDS):
Psychometric properties within a Dutch population. J Sex
Marital Ther 2006;32:289-304.
76. Trudel G, Dargis L, Cadieux J, et al. Validation of the Female
Sexual Function Index (FSFI) and presentation of norms in
older women. Sexologies 2012;21:161-167.
77. Trutnovsky G, Nagele E, Ulrich D, et al. German translation
and validation of the Pelvic Organ Prolapse/Incontinence
Sexual QuestionnaireeIUGA revised (PISQ-IR). Int Urogy-
necol J 2016;27:1235-1244.
78. Vallejo-Medina P, Perez-Duran C, Saavedra-Roa A. Trans-
lation, adaptation, and preliminary validation of the Female
Sexual Function Index into Spanish (Colombia). Arch Sex
Behav 2018;47:797-810.
79. Velten J, Scholten S, Graham CA, et al. Psychometric prop-
erties of the Sexual Excitation/Sexual Inhibition Inventory
for Women in a German sample. Arch Sex Behav 2016;
45:303-314.
80. Verit F, Verit A. Validation of the Female Sexual Function
Index in women with chronic pelvic pain. J Sex Med 2007;
4:1635-1641.
81. Wang H, Lau H-H, Hung M-J, et al. Validation of a Mandarin
Chinese version of the pelvic organ prolapse/urinary inconti-
nence sexual questionnaire IUGAerevised (PISQ-IR). Int
Urogynecol J 2015;26:1695-1700.
82. Wiegel M, Meston C, Rosen R. The Female Sexual Function
Index (FSFI): Cross-validation and development of clinical
cutoff scores. J Sex Marital Ther 2005;31:1-20.
83. Witting K, Santtila P, Jern P, et al. Evaluation of the Female
Sexual Function Index in a population based sample from
Finland. Arch Sex Behav 2008;37:912-924.
660 Neijenhuijs et al84. Wolpe R, Queiroz A, Zomkowski K, et al. Psychometric
properties of the Female Sexual Function Index in the visual
analogue scale format. Sex Health 2017;14:213-220.
85. Wylomanski S, Bouquin R, Philippe H-J, et al. Psychometric
properties of the French Female Sexual Function Index (FSFI).
Qual Life Res 2014;23:2079-2087.
86. Zachariou A, Filiponi M, Kirana P. Translation and validation of
the Greek version of the Female Sexual Function Index
questionnaire. Int J Impot Res 2017;29:171-174.
87. Zohre M, Minoo P, Ali M. Pelvic Organ Prolapse/Urinary
Incontinence Sexual Questionnaire (PISQ-12): psychometric
validation of the Iranian version. Int Urogynecol J 2014;
26:433-439.
88. Chedraui P, Pérez-López FR, Sánchez H, et al. Assessment of
sexual function of mid-aged Ecuadorian women with the
6-item Female Sexual Function Index. Maturitas 2012;
71:407-412.
89. Lee Y, Lim MC, Joo J, et al. Development and validation of the
Korean version of the Female Sexual Function Index-6 (FSFI-
6K). Yonsei Med J 2014;55:1442-1446.
90. Mitchell K, Ploubidis G, Datta J, et al. The Natsal-SF: A vali-
dated measure of sexual function for use in community sur-
veys. Eur J Epidemiol 2012;27:409-418.
91. Pérez-López FR, Fernández-Alonso AM, Trabalón-Pastor M,
et al. Assessment of sexual function and related factors in
mid-aged sexually active Spanish women with the six-item
Female Sex Function Index. Menopause 2012;19:1224-1230.
92. Bartula I, Sherman KA. Development and validation of the
Female Sexual Function Index adaptation for breast
cancer patients (FSFI-BC). Breast Cancer Res Treat 2015;
152:477-488.
93. Burri A, Cherkas L, Spector T. Replication of psychometric
properties of the FSFI and validation of a modified version
(FSFI-LL) assessing lifelong sexual function in an unselected
sample of females. J Sex Med 2010;7:3929-3939.94. Carvalho J, Vieira AL, Nobre P. Latent structures of female
sexual functioning. Arch Sex Behav 2012;41:907-917.
95. Bland JM, Altman DG. Statistical methods for assessing
agreement between two methods of clinical measurement.
Lancet 1986;327:307-310.
96. Bland JM, Altman DG. Agreement between methods of
measurement with multiple observations per individual.
J Biopharm Stat 2007;17:571-582.
97. Carvalheira AA, Brotto LA, Leal I. Women’s motivations
for sex: Exploring the diagnostic and statistical manual,
fourth edition, text revision criteria for hypoactive sexual
desire and female sexual arousal disorders. J Sex Med 2010;
7:1454-1463.
98. Balon R, Segraves RT, Clayton A. Issues for DSM-V: Sexual
dysfunction, disorder, or variation along normal distribution:
Toward rethinking DSM criteria of sexual dysfunctions. Am J
Psychiatr 2007;164:198-200.
99. Gierhart BS. When does a “less than perfect” sex life
become female sexual dysfunction? Obstet Gynecol 2006;
107:750-751.
100. Sungur MZ, Gündüz A. A comparison of DSM-IV-TR and
DSM-5 definitions for sexual dysfunctions: Critiques and
challenges. J Sex Med 2014;11:364-373.
101. de Vet HC, Terwee CB, Ostelo RW, et al. Minimal changes in
health status questionnaires: distinction between minimally
detectable change and minimally important change. Health
Qual Life Outcomes 2006;4:54.
102. Puppo V, Puppo G. RE: Bartula I, Sherman KA. Development
and validation of the Female Sexual Function Index adaptation
for breast cancer patients (FSFI-BC). Breast Cancer Res
Treat 2015;153:705-706.SUPPLEMENTARY DATA
Supplementary data related to this article can be found at
10.1016/j.jsxm.2019.03.001J Sex Med 2019;16:640e660
